Published Online
on May 25, 2006

A more recent version of this article appeared on July 1, 2006

This Article Full Text (PDF) All Versions of this Article: 37/7/1917    most recent 01.STR.0000226651.04862.dav1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weintraub, M. I. Search for Related Content PubMed PubMed Citation Articles by Weintraub, M. I. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Emergency Medical Services Related Collections Acute Stroke Syndromes Emergency treatment of Stroke Thrombolysis

Submitted on February 27, 2006
Revised on March 21, 2006
Accepted on April 19, 2006

Thrombolysis (Tissue Plasminogen Activator) in Stroke. A Medicolegal Quagmire

Michael I. Weintraub MD, FACP, FAAN^*

From the Department of Neurology and Internal Medicine, New York Medical College, Valhalla, NY.

^* To whom correspondence should be addressed. E-mail: miwneuro{at}pol.net.

Background and Purpose--Despite the success of the 1995 National Institutes of Neurological Disorders and Stroke (NINDS) study using IV recombinant tissue plasminogen activator (tPA) within 3 hours in acute stroke and its subsequent FDA approval, there has been a reluctance to use tPA because of safety and efficacy issues with high incidence of intracerebral hemorrhage, and protocol violations.

Summary of Review--The following cases will illustrate the increased number of malpractice lawsuits generated by the controversy of "standard of care" and illustrate and educate clinicians regarding specific issues and how to avoid: (A) Failure to use tPA (loss of chance) or to transfer, Reed versus Granbury Hospital (Texas): acute stroke victim taken to local hospital with tPA available only for cardiology. Wife subsequently transferred patient to nearby stroke center but no tPA given. Defendant verdict; (B) Stroke misdiagnosis (failure to diagnose, loss of chance), Mei versus Kaiser Permanente South (San Francisco, CA): acute stroke while driving with ambulance taking to local hospital. Symptoms were misdiagnosed and neurologist did not see her for 6 hours. Plaintiff verdict; (C) Bleeding complications of therapy/failure of informed consent, Harris versus Oak Valley Hospital (California): acute stroke and hypertension treated with tPA with subsequent development of intracerebral hemorrhage. Patient alleged that tPA should not have been given. Defense verdict; (D) Expert witness testimony, Wojcicki versus Caragher (Massachusetts): a prominent neurologist gave "false and misleading testimony" and the Court found that the neurologist perpetrated a "fraud on the Court" intentionally and deliberately misleading the Court and jury. Court sanctioned the neurologist $88 685; Ensink versus Mecosta County General Hospital (Michigan): neurological testimony (plaintiff expert) regarding potential benefit of using tPA during last available 1 hour of window was felt to be "speculative". Defendant verdict.

Conclusions--Neurologists, emergency room physicians and hospitals are at increased liability risk if they use or do not use tPA. Detailed documentation, informed consent or timely transfer should reduce threat of legal action.

Key words: lawsuits • malpractice • stroke • thrombolytic drugs • tissue plasminogen activator

This article has been cited by other articles:

				L. H. Schwamm, H. J. Audebert, P. Amarenco, N. R. Chumbler, M. R. Frankel, M. G. George, P. B. Gorelick, K. B. Horton, M. Kaste, D. T. Lackland, et al. Recommendations for the Implementation of Telemedicine Within Stroke Systems of Care: A Policy Statement From the American Heart Association Stroke, July 1, 2009; 40(7): 2635 - 2660. [Full Text] [PDF]

				M. J. Alberts, R. A. Felberg, L. R. Guterman, S. R. Levine, and for Writing Group 4 Atherosclerotic Peripheral Vascular Disease Symposium II: Stroke Intervention: State of the Art Circulation, December 16, 2008; 118(25): 2845 - 2851. [Full Text] [PDF]

				E. C. Leira, D. C. Hess, J. C. Torner, and H. P. Adams Jr Rural-Urban Differences in Acute Stroke Management Practices: A Modifiable Disparity Arch Neurol, July 1, 2008; 65(7): 887 - 891. [Abstract] [Full Text] [PDF]

				W. H. Self and P. S. Pang What Do We Really Know About Neurological Misdiagnosis in the Emergency Department? Mayo Clin. Proc., February 1, 2008; 83(2): 252 - 252. [Full Text] [PDF]

				J. A. Edlow, R. E. Rothman, and W. G. Barsan What Do We Really Know About Neurological Misdiagnosis in the Emergency Department? Mayo Clin. Proc., February 1, 2008; 83(2): 253 - 254. [Full Text] [PDF]

				L. R. Caplan Dizziness: How Do Patients Describe Dizziness and How Do Emergency Physicians Use These Descriptions for Diagnosis? Mayo Clin. Proc., November 1, 2007; 82(11): 1313 - 1315. [Full Text] [PDF]

				M. Castellanos, T. Sobrino, M. Millan, M. Garcia, J. Arenillas, F. Nombela, D. Brea, N. Perez de la Ossa, J. Serena, J. Vivancos, et al. Serum Cellular Fibronectin and Matrix Metalloproteinase-9 as Screening Biomarkers for the Prediction of Parenchymal Hematoma After Thrombolytic Therapy in Acute Ischemic Stroke: A Multicenter Confirmatory Study Stroke, June 1, 2007; 38(6): 1855 - 1859. [Abstract] [Full Text] [PDF]

				J. P. Callen Livedoid vasculopathy: what it is and how the patient should be evaluated and treated. Arch Dermatol, November 1, 2006; 142(11): 1481 - 1482. [Full Text] [PDF]

				L. B. Goldstein and J. L. Saver Thrombolysis in Stroke: a Medicolegal Quagmire Stroke, November 1, 2006; 37(11): 2663 - 2663. [Full Text] [PDF]

				M. I. Weintraub Response to Letters by Whiteley et al and Goldstein et al Stroke, November 1, 2006; 37(11): 2664 - 2665. [Full Text] [PDF]